US FDA slams Elite Pharma for adverse reaction monitoring failures
Elite Pharmaceuticals has received a US FDA warning letter for failing to adequately monitor adverse drug experiences (ADEs).
Archives for September 4, 2016
When it comes to vaccine adjuvants, not all alum is equal
Aluminium adjuvants should not be used in trial placebos according to UK scientists who say the differing physical and biological properties of alum salt forms makes some safer than others.